论文部分内容阅读
呼吸道合胞病毒(respiratory syncytial virus,RSV)是导致婴幼儿下呼吸道感染最主要的病原体,目前临床上大多采用支持性治疗。而阿奇霉素是一种已被证实的具有较好疗效的抗菌药物,还具有非抗菌作用的抗炎性,特别对支气管哮喘、囊性肺纤维化等非特异呼吸道炎性反应效果显著。因此本研究选择阿奇霉素治疗164例呼吸道合胞病毒毛细支气管炎患儿,观察其住院时间,现报告如下。
Respiratory syncytial virus (RSV) is the most important causative agent of lower respiratory tract infection in infants and young children. At present, most of the supportive treatments are used clinically. Azithromycin is a proven antimicrobial agent with good curative effect. It also has non-antibacterial and anti-inflammatory effects, especially for nonspecific respiratory inflammatory reactions such as bronchial asthma and cystic fibrosis. Therefore, this study chose azithromycin treatment of 164 cases of respiratory syncytial virus bronchiolitis in children, to observe their hospital stay, are as follows.